Selenium against HPV (human papilloma virus) and Cervical Intraepithelial Neoplasia (CIN)
Update to Antiviral Nutrition (download free sample) protocol by Dr Alex Vasquez posted 20 January 2018; also see previous publications on vitamin D
ICHNFM Courses, Books, Membership, Newsletter
Click corner icon to enlarge video below
Antiviral Nutrition Update #2 for 2018
Written and recorded by Dr Alex Vasquez
The video of this presentation is archived at ichnfm.org/hpv2, and the transcript in PDF format—which is considered the final and citable version—is archived at academia.edu/35798286; any corrections or updates will be made to the PDF file. Observe that this video presentation is truly an *update* subsequent to previous publications and that therefore not all sources are cited; for citations, see the video, and for complete citations regarding the protocol in its entirety, see the book Antiviral Strategies and Immune Nutrition or the ebook version titled Antiviral Nutrition.
“Hello, everybody. Dr. Alex Vasquez here with Antiviral Nutrition Update #2 for 2018. Again, these updates are based upon the foundational information and sources that I discussed previously. Namely, the books, articles, videos/presentations, and blogs. You have those listed for you again here.
Book: Antiviral Strategies and Immune Nutrition (2014)
eBook: Antiviral Nutrition (Kindle ebook, 2014)
Tutorials: AntiViral Strategies and Immune Nutrition: Antiviral Nutrition (video, 2014)
Again, the book Antiviral Strategies and Immune Nutrition was published as an ebook under the title of Antiviral Nutrition. I also have two journal articles here, also a conference presentation, and a series of video tutorials that help to support this information.
As I mentioned before, one of our goals is to have a structured understanding of viral infections, and from that structured understanding to arrive at a comprehensive antiviral strategy. In other words, if you can't deconstruct the pathophysiologic event—in this case we're talking about viral infections—then you're pretty much trapped in the phenomena of viral infections. Achievement of goals is effected via strategies, and each strategy is effected by its tactics. What that looks like visually is we have goals—in this case the prevention and treatment of viral infections. Supporting that goal is the strategy of addressing each one of the major components of a viral infection. So, we want to deconstruct and address each major aspect of what we call viral infections generally, and to support that strategy, we're going to use a specific tactic, and that is the use of these clinical protocols for each component of the above-mentioned strategy.
Graphically, that's represented by these two images from my book. Again, Antiviral Strategies and Immune Nutrition, published as an Amazon Kindle ebook as Antiviral Nutrition (the Kindle software is free from Amazon and allows reading on any smartphone, iPad/tablet or computer). We want to address 1) the viral component, we want to address 2) the replication of that virus, we want to address 3) immunonutrition, and we want to 4) support cellular and systemic health, as well.
In Antiviral Nutrition Update #1 for 2018 (archived at ichnfm.org/hpv1), we looked at this article “Effects of Long-Term Vitamin D Supplementation on
Regression and Metabolic Status of Cervical Intraepithelial Neoplasia.” You've got all of the information summarized for you here, so I won't go through it in its entirety, but you're certainly welcome to pause the video and read the screen if you want to get the information from our previous conversation. Likewise, I also reviewed the biological effects of vitamin D3 supplementation/optimization mostly specific to the treatment of viral infections. Then, I provided some clinical context and conclusions. Again, you're welcome to pause the video and review that previous information. My previous publications on vitamin D from Alternative Therapies in Health and Medicine, British Medical Journal, JAMA—Journal of the American Medical Association, and Journal of Clinical Endocrinology and Metabolism are available as a PDF download archived at ichnfm.org/d.
One of the preventative measures for HPV viral infection related illness is the antiHPV vaccination. I consider that vaccination to be expensive and the data has shown quite conclusively that this vaccination can produce many biologically proven adverse effects including autoimmunity (e.g., acute disseminated
encephalomyelitis), neuroinflammation, infertility, and death, and it really doesn't provide any collateral benefits. As published in The Washington Times (December 31, 2014):
“Judicial Watch announced it has received documents from the Department of Health and Human Services (HHS) revealing that its National Vaccine Injury Compensation Program (VICP) has awarded $5,877,710 dollars to 49 victims in claims made against the highly controversial HPV (human papillomavirus) vaccines.… The adverse reaction reports detail 26 new deaths reported between September 1, 2010 and September 15, 2011 as well as incidents of seizures, paralysis, blindness, pancreatitis, speech problems, short term memory loss and Guillain-Barré Syndrome. The documents come from the FDA’s Vaccine Adverse Event
Reporting System (VAERS) which is used by the FDA to monitor the safety of vaccines."
So, when we actually look at the data, we do see some concerns about the human papillomavirus vaccine. You can see that this was published by the American College of Pediatricians in January of 2016, citing some concern about premature ovarian failure, premature menopause. These are legitimate concerns related to the aluminum adjuvant, especially when combined with another vaccine component, polysorbate 80 (a patented form of which is sold under the name “Tween 80”), which has been shown to cause reproductive abnormalities in animal studies. Importantly noted is the clinical investigation published in Annals of Allergy, Asthma & Immunology—the scholarly medical journal published by the American College of Allergy, Asthma and Immunology—which stated,
“Polysorbate 80 was identified as the causative agent for the anaphylactoid reaction of nonimmunologic origin in the patient. Polysorbate specific IgE antibodies were not identified in enzyme-linked immunosorbent assay and immunoblot examinations, confirming the nonimmunologic nature of the anaphylactoid reaction. CONCLUSIONS: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.”
In the human clinical literature, we see documentation of series adverse events after HPV vaccination. This was a critical review of randomized trials and
post-marketing case series. From Immunology Research 2017, “Severe Somatoform and Dysautonomic Syndromes after HPV vaccination” was a case series and review of the literature. Here also, we see immunological studies showing abnormalities in cerebral spinal fluid from patients with CNS symptoms after HPV vaccination.
In our last conversation, we talked about vitamin D. We looked at some of the information showing that it can actually promote regression of cervical
intraepithelial neoplasia grade one (CIN1), and that's been shown in an oral study using approximately 3500 international units (IU) per day of vitamin D3. This was also shown in a topical study using vaginally applied vitamin D and you can see that described here in a publication from DermatoEndocrinology in 2014.
We're going to maintain this theme talking about nutrition against HPV infection and its consequences today. For Antiviral Nutrition Update #2 for 2018,
we're going to look at this article from the British Journal of Nutrition 2015, “The Favorable Effects of Long-term Selenium Supplementation on Regression of Cervical Tissues and Metabolic Profiles of Patients with Cervical Intraepithelial Neoplasia.” This, like the other one, is a randomized, double-blind, placebo-controlled trial. You've got the citation and you also have the digital object identifier (DOI) in the upper right hand corner. You can pause the video if you want to read the abstract. Otherwise, I'll provide you my summary here.
Again, the title of this article: “The Favorable Effects of Long-term Selenium Supplementation on Regression of Cervical Tissues and Metabolic Profiles of
Patients with Cervical Intraepithelial Neoplasia” [caused by HPV viral infection], British Journal of Nutrition, December of 2015. This is a randomized, double-blind, placebo controlled trial, with approximately 50 women with cervical intraepithelial neoplasia grade one. The intervention here was 200 mcg of selenium for six months. The results showed that after six months of taking selenium supplements, a greater percentage of women in the selenium group had regressed their CIN1 that was 88% versus 56% in the placebo group. They also noted significant decreases in fasting plasma glucose levels, reduced insulin levels, improved insulin sensitivity, reduced triglycerides, and elevated HDL. That suggests greatly improved metabolic efficiency in terms of using glucose and insulin sensitivity, versus insulin resistance. They showed improved antioxidant defenses with elevated glutathione and a reduction in oxidative stress markers, and as we would expect, they showed excellent safety from 200 mcg of selenium for six months.
Let's look at some of the antiviral mechanism of selenium. Number one, selenium reduces viral mutations. So, when we look at the antiviral strategy that
I've outlined, we see that selenium has antiviral effects by blocking viral mutations. Oxidant driven mutagenesis promotes viral immune escape and selenium clearly retards this process. So, that might be one of the mechanisms of benefit here from selenium supplementation in the treatment of HPV related disease. Number two, we also know that selenium inhibits the NFkB pathway to retard viral replication. Viruses famously hijack this NFkB pathway to promote their own replication. So, again, selenium helps with a direct antiviral effect and it also blocks viral replication. Number three, selenium provides some antioxidant benefits via glutathione peroxidase specifically. Thereby, obviously working in tandem with riboflavin, which is the co-factor for glutathione reductase. Selenium helps to prevent premature immunosenesence due to immunoactivation and oxidation. Number four, selenium promotes lymphatic flow. This has been demonstrated in studies showing that selenium is effective in the treatment of post-nodectomy lymphedema. Selenium also supports thyroid function and—again—it is a general antioxidant. So, I think we could reasonably say that selenium provides cellular and systemic support in addition to its other benefits in combating viral infections and supporting immune health.
Now, let's contextualize this within the overall strategy, the Antiviral Nutrition strategy. Our goal with this strategy is the safe and effective prevention and treatment of viral infections and diseases that are secondary to those viral infections. Our aspirational goal beyond that rather narrow primary goal is the ideal, which is our treatments should be safe, they should have no side effects, they should be effective, they should be widely available and affordable. They should have minimal or no drug interactions and we'd love some collateral benefits. Furthermore, we also want to respect patient autonomy and human rights. This was previously known as "medical ethics" before the era of mandatory medicalization.
Our strategy to support those goals is to deconstruct the phenomena of what we think of when we talk about viral infections into its main components, and
our tactic is to effectively address each component with an effective, and safe clinical protocol. Thus far, in this conversation for 2018, we've discussed vitamin D3 and here, I've discussed selenium.
Thank you very much for attending this very brief video update and I will provide some more information as this series progresses. Again, here, you've got the previously mentioned foundational information upon which we're providing these updates. Specifically, antiviral strategies and also antiviral nutrition. That was also published in my 2016 book Inflammation Mastery 4th Edition (paper book and digital) and also in a smaller volume, the two-volume set published under the title Textbook of Clinical Nutrition and Functional Medicine. In this case, it was in chapter 4; so, that's Volume One.
Thank you again for your attention during this very brief and efficient video update and I look forward to sharing more information with you soon.
Citation: Vasquez A. Antiviral Nutrition Update #2 for 2018. Video presentation (ichnfm.org/hpv2) and official transcript (academia.edu/35798286) 2018 January
Primary reference: Antiviral Strategies and Immune Nutrition amazon.com/dp/1502894890/ also published in digital ebook format as Antiviral Nutrition
(Kindle ebook) amazon.com/dp/B00OPDQG4W. Also published in Inflammation Mastery, 4th Edition amazon.com/dp/B01KMZZLAQ/ and
Textbook of Clinical Nutrition and Functional Medicine, vol. 1: Essential Knowledge for Safe Action and Effective Treatment amazon.com/dp/B01JDIOHR6/
 Vasquez et al. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. Altern Ther Health Med. 2004
 Vasquez et al. Calcium and vitamin D in preventing fractures: Data are not sufficient to show inefficacy. BMJ: British Medical Journal 2005
 Muanza, Vasquez et al. Isoflavones and postmenopausal women [letter]. JAMA: Journal of the American Medical Association 2004
 Gordon et al. Treatment of Hypovitaminosis D in Infants and Toddlers. Journal Clinical Endocrinology Metabolism 2008
 Sekiguchi et al. Two Cases of Acute Disseminated Encephalomyelitis Following Vaccination against Human Papilloma Virus. Intern Med. 2016;55(21):3181-3184
 Takahashi et al. Immunological studies of cerebrospinal fluid from patients with CNS symptoms after human papillomavirus vaccination. J Neuroimmunol. 2016
 Martínez-Lavín M, Amezcua-Guerra L. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clin
Rheumatol. 2017 Oct;36(10):2169-2178
 "The adverse reaction reports detail 26 new deaths reported between September 1, 2010 and September 15, 2011 as well as incidents of seizures, paralysis,
blindness, pancreatitis, speech problems, short term memory loss and Guillain-Barré Syndrome. The documents come from the FDA’s Vaccine Adverse Event
Reporting System (VAERS) which is used by the FDA to monitor the safety of vaccines." Lind P. U.S. court pays $6 million to Gardasil victims. The Washington
Times December 31, 2014
 American College of Pediatricians, primary author Scott S. Field, MD. New Concerns about the Human Papillomavirus Vaccine. January 2016. acpeds.org/the-
college-speaks/position-statements/health-issues/new-concerns-about-the-human-papillomavirus-vaccine. Citation of this publication does not imply endorsement of
 Gherardi et al. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015 Feb 5;6:4
 U.S. National Library of Medicine National Center for Biotechnology Information. pubchem.ncbi.nlm.nih.gov/compound/443315. Polysorbate 80 is a nonionic
surfactant, emulsifier, and excipient that is used to stabilize aqueous formulations of medications including vaccinations for parenteral administration. Tween 80—
Tween is a registered trademark of Croda Americas, Inc.
 "Neonatal female rats were injected ip (0.1 ml/rat) with Tween 80 in 1, 5 or 10% aqueous solution on days 4-7 after birth. Treatment with Tween 80 accelerated
maturation, prolonged the oestrus cycle, and induced persistent vaginal oestrus. The relative weight of the uterus and ovaries was decreased relative to the
untreated controls. Squamous cell metaplasia of the epithelial lining of the uterus and cytological changes in the uterus were indicative of chronic oestrogenic
stimulation. Ovaries were without corpora lutea, and had degenerative follicles." Gajdová et al. Delayed effects of neonatal exposure to Tween 80 on female
reproductive organs in rats. Food Chem Toxicol. 1993 Mar;31(3):183-90
 Coors et al. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005 Dec;95(6):593-9